ArticleBMC pediatrics2026
Early hypotonia and visual regression as presenting features of peroxisome biogenesis disorder: an Egyptian case report.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPeroxisome biogenesis disorders (PBDs) are rare autosomal recessive neurodegenerative diseases caused by variants in Peroxin (PEX) genes, leading to defective peroxisome assembly and multisystem dysfunction. The PEX12 variant NM_000286.3: c.1047_1049del (NP_000277.1: p.Gln349del) has been described almost exclusively in Egyptian patients, suggesting a founder effect. We present the first Egyptian case with this variant showing bilateral optic atrophy, expanding the known clinical phenotype of PEX12-related PBD. CASE PRESENTATION: A six-year-old Egyptian boy, born to first-cousin parents, presented with early hypotonia, developmental regression, visual inattention, and sensorineural hearing loss. Early milestones were initially normal, followed by progressive motor and cognitive decline beginning at age three. Ophthalmologic examination revealed bilateral optic atrophy, and audiologic testing confirmed profound sensorineural hearing loss. Brain Magnetic Resonance Imaging (MRI) showed bilateral periventricular and cerebellar white matter hyperintensities, with restricted diffusion in the involved areas and corpus callosum involvement. Laboratory studies were unremarkable, but trio whole-exome sequencing identified a homozygous PEX12 deletion (c.1047_1049del), confirming a diagnosis within the Zellweger spectrum of peroxisome biogenesis disorders. The patient was managed with supportive multidisciplinary care, including levetiracetam for seizure control, physiotherapy, nutritional support, and regular follow-up. At one-year follow-up, seizures were controlled, but severe neurological disability persisted.
conclusionThis case highlights a rare PEX12-related peroxisome biogenesis disorder with optic atrophy-an unreported feature of this variant-broadening its phenotypic spectrum. It underscores the diagnostic value of whole-exome sequencing when biochemical tests are inconclusive and emphasizes the need for increased awareness of founder variants in populations with high consanguinity to enable earlier diagnosis, counseling, and targeted screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.